加载中...

MedXY AI/MedXY News/Tag: clinical trial

MedXY News

EnglishTag

clinical trial

170 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive dec

Section: NeurologyDec 25, 2025

Efficacy of mHealth Interventions for Smoking Cessation in Tuberculosis Patients: Insights from a Cluster Randomized Clinical Trial

Efficacy of mHealth Interventions for Smoking Cessation in Tuberculosis Patients: Insights from a Cluster Randomized Clinical Trial

An mHealth text messaging intervention significantly improves smoking cessation rates and reduces mortality among TB patients compared to usual care, supporting its implementation in TB programs.

Section: AIDec 24, 2025

Yoga vs Physical Conditioning: Evaluating Sleep Benefits in Women with Urinary Incontinence

Yoga vs Physical Conditioning: Evaluating Sleep Benefits in Women with Urinary Incontinence

A secondary analysis of a randomized clinical trial finds that Hatha yoga does not provide superior sleep benefits compared to general physical conditioning in women with urinary incontinence, despite the strong correlation between nocturna

Section: newsDec 22, 2025

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liv

Section: Infectious DiseasesDec 19, 2025

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.

Section: Diabetes & EndocrinologyDec 17, 2025

Rethinking Oxygen Strategies for Preterm Infant Resuscitation: Evidence from TORPIDO, IPD-MA, and DCC Trials

Rethinking Oxygen Strategies for Preterm Infant Resuscitation: Evidence from TORPIDO, IPD-MA, and DCC Trials

Recent trials and meta-analyses challenge assumptions about optimal initial oxygen levels for preterm resuscitation.

Section: Critical CareDec 17, 2025

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.

Section: Diabetes & EndocrinologyDec 14, 2025

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Section: Allergy & ImmunologyDec 7, 2025

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even

Section: Infectious DiseasesNov 24, 2025

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan

Section: Clinical UpdatesNov 24, 2025

Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT

Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT

The UMC‑UPPERGI‑01 randomized trial (n=208) found laparoscopic distal gastrectomy with D2 lymphadenectomy had similar 30‑day morbidity and mortality to open surgery for clinical T4a gastric cancer, despite longer operative times and modestl

Section: General SurgeryNov 14, 2025

Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA

Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA

In the MARIPOSA randomized, double-blind exploratory analysis, lazertinib monotherapy showed comparable progression-free survival, response rates, overall survival (interim), and tolerability to osimertinib in treatment-naive EGFR‑mutant ad

Section: newsNov 12, 2025

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasoph

Section: newsNov 11, 2025

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety

Section: newsNov 11, 2025

Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis

Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis

A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.

Section: GastroenterologyNov 9, 2025

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial

The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.

Section: GastroenterologyNov 9, 2025

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.

Section: Allergy & ImmunologyOct 28, 2025

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

This article reviews a phase 3 trial analyzing sotatercept’s efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

Section: CardiologyOct 26, 2025

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

Section: newsOct 26, 2025

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Section: Internal MedicineOct 26, 2025

Prev 1 2 3 4 5 9 Next